ETV1 and prostate carcinoma: This study elucidates the intricate interplay between ETS rearrangements and the EGFR‐STATs signaling pathway in PCa cells and underscores the potential of a personalized targeted therapy for the molecular subgroup of prostate carcinomas characterized by ETV1 overexpression, which represents ~ 10% of all PCa patients and is associated with a worse prognosis.